D1 PD Purchase Description.pdf

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

PURCHASE DESCRIPTION

1. Name of Item or Project Title: Purchase of Angio-Proteomie primary human endothelial cells of varying tissue origins (Brand-Name Only). This is a COVID-19

Action.

2. Statement of Need and Purpose: The Division of Preclinical Innovation (DPI) within the

National Center for Advancing Translational Sciences (NCATS) seeks Angio-Proteomie primary human endothelial cells of varying tissue origins for use in DPI-APP_Biology

Antiviral Drug Development IDDA DPI (8051491).

3. Background Information and Objective: The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives.

NCATS is one of 27 Institutes and Centers at the NIH and its mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions.

The NCATS DPI plans, conducts and uses both internal and contract resources to advance collaborative research projects across the preclinical phases of the translational science spectrum.

NCATS has become a key partner in the Antiviral Program for Pandemics (APP), a multi-agency initiative that includes National Institute of Allergy and Infectious Diseases

(NIAID) and Biomedical Advanced Research and Development Authority (BARDA), to accelerate antiviral development through early discovery and preclinical development of safe and effective oral antivirals. The initial priority for the APP is to develop treatments for SARS-CoV-2 and other coronaviruses, with the program expanding to address other virus families with pandemic potential. NCATS will apply its proficiency in drug discovery and development and its cutting-edge technologies to fill critical needs of the APP, such as (i) target validation, (ii) high-throughput screening (HTS) for drug starting points, (iii) medicinal chemistry for lead optimization, and (iv) preclinical, investigational new drug

(IND)-enabling development.

The APP is also tasked with identifying and developing antivirals for a variety of viruses of outbreak and pandemic potential, including a number of viruses that cause vascular damage (e.g. bunyavirales viruses, flaviviruses, alphaviruses).

NCATS DPI will use 2d and 3d endothelial cells or vascularized tissue and will use these models to screen for antivirals within APP against select virus panels using the primary human endothelial cells of varying tissue origins.

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

NCATS has previously used Angio-proteomie HUVECS, HUVEC RFP/GFPs, human pulmonary endothelial cells +/- GFP/RFP, human microvascular brain endothelial cells and validated them for appropriate markers and vascular function in 3d models as well as growth characteristics in 2D. NCATS has extensively characterized endothelial cells from Angio-proteomie for vascular formation and have optimized conditions for this cell sourcing that would have to be extensively reoptimized upon vendor switching due to media, supplement, and culturing conditions.

4. Generic Name of Product: Primary human endothelial cells of varying tissue origins.

5. Brand-Name Purchase Description: The primary human endothelial cells of varying tissue origins (Brand-name only) that meets the need of this requirement are listed, as follows:

Part Number Description Size Quantity cAP-0012RFP RFP Expressing Human Liver Sinusoidal

Microvascular Endothelial Cells

1.0 Frozen Vial 15 vials

cAP-0002 Human Brain Microvascular Endothelial Cells 1.0 Frozen Vial 15 vials cAP-0002GFP GFP Expressing Human Brain Microvascular

Endothelial Cells

1.0 Frozen Vial 15 vials

cAP-0120GFP GFP-Human Pulmonary Artery Endothelial Cells

(HPuAECs)

1.0 Frozen Vial 15 vials

cAP-0001 Human Umbilical Vein Endothelial Cells

(HUVECs)

1.0 Frozen Vial 15 vials

cAP-0032GFP GFP Expressing Human Pulmonary

Microvascular Endothelial Cells

1.0 Frozen Vial 15 vials

cAP-0001RFP RFP Expressing Human Umbilical Vein

Endothelial Cells

1.0 Frozen Vial 15 vials

6. Salient characteristics The salient characteristics of the primary human endothelial cells of varying tissue origins include:

• Derived from human.

• Non-fetal

• Viable

• From indicated tissue sources

• Must have RFP or GFP when indicated in product description above

• Must be able to grow in 2D and 3D culture

• Must be delivered on dry ice or in liquid nitrogen

• Handling and Shipping to NCATS, FOB Destination.

7. Quantity: Total of 105 vials of primary human endothelial cells of varying tissue origins, as provided in the Purchase Description.

8. Delivery Date: Delivery is required within three (3) weeks after receipt of order (ARO), Delivery shall be made to the National Center for Advancing Translational Sciences

(NCATS), at 9800 Medical Center Drive, Rockville, MD 20850, with FOB Destination, in accordance with quantities described in the Purchase Description.